Hence, primary resistance of BRAF-mutant thyroid cancer cell lines to vemurafenib is overcome by HER kinase inhibitors and further abrogated by YAP inhibition in vitro and in vivo. This evidence concerns the gene YAP1 and thyroid gland carcinoma.